Bogna Klimek

Bogna Klimek

Auto-generated profile, based on publicly available information

Bogna Klimek

University of Geneva 1 Department of Pathology and Immunology Geneva

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KSKarin Steinbach
Karin Steinbach
IVIlena Vincenti
Ilena Vincenti
KEKristof Egervari
Kristof Egervari
MKMario Kreutzfeldt
Mario Kreutzfeldt
FMFranziska van der Meer
Franziska van der Meer
DMDoron Merkler
Doron Merkler
Epidemiological studies associate viral infections during childhood with the risk of developing autoimmune disease during adulthood. However, the mechanistic link between these events remains elusive. We report that transient viral infection of the brain in early life, but not at a later age, precipitates brain autoimmune disease elicited by adoptive transfer of myelin-specific CD4+ T cells at sites of previous infection in adult mice. Early-life infection of mouse brains imprinted a chronic inflammatory signature that consisted of brain-resident memory T cells expressing the chemokine (C-C motif) ligand 5 (CCL5). Blockade of CCL5 signaling via C-C chemokine receptor type 5 prevented the formation of brain lesions in a mouse model of autoimmune disease. In mouse and human brain, CCL5+ TRM were located predominantly to sites of microglial activation. This study uncovers how transient brain viral infections in a critical window in life might leave persisting chemotactic cues and create a long-lived permissive environment for autoimmunity.

14 April 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
NFNicolas Fonta
Nicolas Fonta
NPNicolas Page
Nicolas Page
BKBogna Klimek
Bogna Klimek
MPMargot Piccinno
Margot Piccinno
GLGiovanni Di Liberto
Giovanni Di Liberto
DMDoron Merkler
Doron Merkler
In chronic inflammatory disorders of the central nervous system (CNS), tissue-resident self-reactive T cells perpetuate disease. The specific tissue factors governing the persistence and continuous differentiation of these cells remain undefined but could represent attractive therapeutic targets. In a model of chronic CNS autoimmunity, we find that oligodendrocyte-derived IL-33, an alarmin, is key for locally regulating the pathogenicity of self-reactive CD8+ T cells. The selective ablation of IL-33 from neo–self-antigen–expressing oligodendrocytes mitigates CNS disease. In this context, fewer self-reactive CD8+ T cells persist in the inflamed CNS, and the remaining cells are impaired in generating TCF-1low effector cells. Importantly, interventional IL-33 blockade by locally administered somatic gene therapy reduces T cell infiltrates and improves the disease course. Our study identifies oligodendrocyte-derived IL-33 as a druggable tissue factor regulating the differentiation and survival of self-reactive CD8+ T cells in the inflamed CNS. This finding introduces tissue factors as a novel category of immune targets for treating chronic CNS autoimmune diseases.

13 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NFNicolas Fonta
Nicolas Fonta
NPNicolas Page
Nicolas Page
BKBogna Klimek
Bogna Klimek
MPMargot Piccinno
Margot Piccinno
GLGiovanni Di Liberto
Giovanni Di Liberto
DMDoron Merkler
Doron Merkler
In chronic inflammatory disorders of the central nervous system (CNS), tissue-resident self-reactive T cells perpetuate disease. The specific tissue factors governing the persistence and continuous differentiation of these cells remain undefined but could represent attractive therapeutic targets. In a model of chronic CNS autoimmunity, we find that oligodendrocyte-derived interleukin-33 (IL-33), an alarmin, is key for locally regulating the pathogenicity of self-reactive CD8+ T cells. The selective ablation of IL-33 from neo-self-antigen-expressing oligodendrocytes mitigates CNS disease. In this context, fewer self-reactive CD8+ T cells persist in the inflamed CNS, and the remaining cells are largely locked into a stem-like precursor program, failing to form TCF-1 low effector progeny. Importantly, interventional IL-33 blockade by locally administered somatic gene therapy reduces T cell infiltrates and improves the disease course. Our study identifies oligodendrocyte-derived IL-33 as a druggable tissue factor regulating the differentiation and survival of self-reactive CD8+ T cell in the inflamed CNS. This finding introduces tissue factors as a novel category of immune targets for treating chronic CNS autoimmune diseases.